No Detail Found!

Celecoxib and bevacizumab synergistically inhibit non-small cell lung cancer by inducing apoptosis and modulating VEGF and MMP-9 expression

Author(s)
Abdul Qadir Department of Pharmacology, United Medical and Dental College,Karachi,Pakistan
Zurqa Khalid Department of Physiology, Dow Medical College, Dow University of Health Sciences,Karachi,Pakistan
Fareha Kashan Theba Department of Physiology, Dow Dental College, Dow University of Health Sciences,Karachi,Pakistan
Muhammad Mujtaba Ali Department of Pharmacology, United Medical and Dental College,Karachi,Pakistan
Mahayrookh Asif Department of Pharmacology, Dow International Medical College, Dow University of Health Sciences,Karachi,Pakistan
Fatima Rizvi Department of Pharmacology, Dow International Medical College, Dow University of Health Sciences,Karachi,Pakistan
Abstract
Lung cancer is the most typical form of cancer that results in death worldwide. Patients with non-small cell lung cancer (NSCLC) have an around 15% survival rate despite of advancement in cancer treatment. This study aimed to evaluate the combined effect of celecoxib and bevacizumab on NSCLC using A549 cells as an in vitro model. The A549 cells were culture and treated with celecoxib, bevacizumab and their combination and the cell proliferation was assessed using MTT assay, whereas cell apoptosis was analyzed using flowcytometry. The effects on the apoptotic genes were examined using western blotting, while qPCR was used for analyzing the VEGF and MMP-9 expression. Celecoxib, bevacizumab and their combination exhibited a dose dependent inhibition (p<0.001). The rate of apoptosis was 14.1% and 26.5% but when the two drugs were combined, the rate of apoptosis was significantly increased due to synergism by 52.2% (p<0.001). Western blotting displayed that co-treatment significantly upregulated proapoptotic genes (caspase-3 and -9) and downregulated anti-apoptotic gene (Bcl-2) (p<0.001). Additionally, VEGF and MMP-9 expression were both significantly reduced with co-treatment compared to the control (p<0.001). Celecoxib combined with bevacizumab synergistically inhibited NSCLC by inducing apoptosis and modulating VEGF and MMP-9 expression.
Publication Details
Page(s) 501-506
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 36, Issue: 2, Year: 2023

Request the full text from PASTIC

Keywords
Bevacizumab, Non-small Cell Lung Cancer, Celecoxib
0

Citations

0

Downloads

100

Views